[144] Edwards Lifesciences Corp SEC Filing

Rhea-AI Filing Summary

Form 144 filed for Edwards Lifesciences (EW) discloses a planned insider sale of 4,114 common shares—acquired via equity compensation on 17-Feb-2023—through broker Charles Schwab. The shares represent <0.001% of the company’s ~586.6 million shares outstanding and carry an estimated market value of $326,900. The filer intends to execute the trade on or after 28-Jul-2025 on the NYSE.

The same insider, Daniel J. Lippis, previously sold 330 shares on 09-May-2025 for gross proceeds of $24,560. No other material information, earnings data, or corporate events are included in this notice.

Insights

Securities Analyst

TL;DR: Minor Form 144 filing shows ~$327k insider sale, <1bp of float; immaterial to valuation, signals routine diversification.

This notice reveals a small planned disposition relative to Edwards Lifesciences’ multibillion-dollar market cap. The aggregate value and share count are negligible and unlikely to affect float, liquidity, or price discovery. Prior 330-share sale reinforces a pattern of incremental diversification rather than strategic signaling. Absent accompanying negative disclosures, I view the filing as routine and not price-moving.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	4114	326900.00	586600000	07/28/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/17/2023	Restricted Stock Lapse - see remarks	EDWARDS LIFESCIENCES CORPORATION			4114	02/17/2023	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel J. Lippis ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	05/09/2025	330	24560.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Edwards Lifesciences (EW) shares are being sold under this Form 144?

The insider plans to sell 4,114 common shares.

What is the estimated dollar value of the proposed EW share sale?

The filing lists an aggregate market value of approximately $326,900.

When is the planned sale date for the EW shares?

The approximate sale date disclosed is 28-Jul-2025.

Who is the selling shareholder named in the Form 144?

The filing identifies Daniel J. Lippis as the seller.

How many EW shares has the insider sold in the past three months?

He previously sold 330 shares on 09-May-2025 for $24,560.